Across 14 glioma stem cell lines and four synergy models, the synergy vs. CSS scores indicate a range of ‘good-to-potent’ additivity using a FAK+MEK inhibitor combination, with synergy observed in some GBM stem cell lines. Here, MAP2K7 is linked to glioblastoma.